Basic Info
  • Grade: Pharmaceutical Grade

    Factory Location: Changzhou

    Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

  • Monthly Production Capacity: 500kgs

    Contract Manufacturing: CRO,CMO

    Packaging Information: 1kgs,5kgs,10kgs,25kgs,

  • Delivery Lead Time: 1 week

    Sample Provided: yes

    Payment Terms: L/C

    Mavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM). It received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans. Mavacamten was also approved by Health Canada in October 2022 and by EMA in July 2023 for the same indication.

Send your message to this supplier
  • From:
  • To:
    Asia Talent Chemical Limited.
  • Send a Copy to this Email
  • Message:
    Upload Images / Files
    - Supports jpg, jpeg, png,
     gif, pdf, doc, docx,
     xls, xlsx, txt, rar and zip
    - Max upload 3 files;
     Max  total size: 3MB
    (0/3)

    Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now

  • Verification:
PharmaSources Customer Service